The results also indicated that the Ki-67 index was an independent predictor of recurrence-free survival (RFS) among GIST patients, and that Ki-67 index >8% can complement the modified NIH criteria to distinguish between different outcomes in patients with high-risk GIST and adverse effects of adjuvant imatinib therapy. The gene discussed is MKI67; the disease is gastrointestinal stromal tumor.